Most IVF add-on procedures show little or no evidence of improving success rates despite costing patients thousands of dollars [1].
This finding challenges the widespread use of supplemental fertility treatments that parents often purchase in hopes of increasing the likelihood of a successful pregnancy. Because these procedures can represent a significant financial burden, the lack of proven efficacy raises questions about the ethics of their marketing.
The findings come from a systematic review and meta-analysis of IVF add-on treatments [2]. The researchers evaluated whether these supplemental procedures provide a measurable benefit to patients to help prospective parents understand the cost-benefit balance [2].
The results of the study were published in the scientific journal The Lancet Obstetrics [2]. The review concluded that the majority of these add-ons lack sufficient evidence to support their use in improving fertility outcomes [2].
Financial costs remain a primary concern for patients. The study notes that these add-on treatments may cost thousands of dollars per patient [1]. Despite the high price point, the data suggests these expenses do not correlate with higher success rates for the patients involved [1].
The research suggests a gap between the clinical evidence available and the services offered at many fertility clinics. By synthesizing available data, the meta-analysis provides a broader look at the efficacy of these interventions than individual clinic reports often provide [2].
“Most IVF add-on procedures show little or no evidence of improving success rates”
This study highlights a systemic issue in reproductive medicine where commercial availability often outpaces clinical validation. For patients, it suggests that spending additional funds on supplemental IVF procedures may not increase the probability of a live birth, shifting the focus toward standardized care over expensive, unproven 'extras.'
